LAPACT: An open-label, multicenter phase II trial of nab-paclitaxel (nab-P) plus gemcitabine (Gem) in patients (pts) with locally advanced pancreatic cancer (LAPC).

被引：1

作者：

Philip, Philip Agop

Lacy, Jill

Dowden, Scot D.

Sastre, Javier

Bathini, Venu Gopal

Cardin, Dana Backlund

Ma, Wen Wee

Sobrero, Alberto F.

Koski, Sheryl L.

Borg, Christophe

Tonini, Giuseppe

Rivera, Fernando

Hwang, Jimmy J.

Knoble, Jeanna L.

Al Baghdadi, Tareq

Saif, Wasif M.

Meiri, Eyal

Kayitalire, Louis

Li, Jack

Hammel, Pascal

机构：

[1] Karmanos Canc Inst, Detroit, MI USA

[2] Yale Univ, Sch Med, Dept Med Oncol, New Haven, CT USA

[3] Tom Baker Canc Clin, Calgary, AB, Canada

[4] Hosp Clin San Carlos, Madrid, Spain

[5] Univ Massachusetts, Sch Med, Worcester, MA USA

[6] Vanderbilt Univ, Med Ctr, Vanderbilt Ingram Canc Ctr, Nashville, TN USA

[7] Roswell Pk Canc Inst, Buffalo, NY 14263 USA

[8] IRCCS AOU San Martino IST, Genoa, Italy

[9] Cross Canc Inst, Edmonton, AB T6G 1Z2, Canada

[10] CHU Besancon, F-25030 Besancon, France

[11] Campus Biomed Univ Rome, Dept Med Oncol, Rome, Italy

[12] Hosp Univ Marques de Valdecilla, Santander, Spain

[13] Georgetown Univ, Dept Med & Oncol, Washington, DC USA

[14] Georgetown Univ, Innovat Ctr Biomed Informat, Lombardi Comprehens Canc Ctr, Washington, DC USA

[15] Mark H Zangmeister Ctr, Columbia, OH USA

[16] IHA Hematol Oncol Consultants, Ypsilanti, MI USA

[17] Tufts Univ, Sch Med, Tufts Canc Ctr, Boston, MA 02111 USA

[18] Southeastern Reg Med Ctr, Canc Treatment Ctr Amer, Atlanta, GA USA

[19] Celgene Corp, Summit, NJ USA

[20] Hop Beaujon, Clichy, France

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2016年 / 34卷 / 04期

关键词：

D O I：

10.1200/jco.2016.34.4_suppl.tps477

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

TPS477

引用

页数：1

共 50 条

[1] The international, open-label, multicenter phase 2 LAPACT trial of nab-paclitaxel (nab-P) plus gemcitabine (Gem) for patients with locally advanced pancreatic cancer (LAPC)
Pascal, Hammel
Jill, Lacy
Fabienne, Portales
Alberto, Sobrero
Beatriz, Garca-Paredes
Edward, Kim
Fernando, Rivera
Jose Luis, Manzano
Eric, Terrebonne
Venu, Bathini
Scot, Dowden
Jamil, Asselah
Jack, Shiansong Li
Thomas, Nydam
Louis, Kayitalire
Philip, Philip
ANNALS OF ONCOLOGY, 2016, 27 : 78 - 79
[2] International phase II trial of weekly nab-paclitaxel (nab-P) plus gemcitabine (Gem) in patients with locally advanced pancreatic cancer (LAPC): LAPACT
Philip, P.
Kayitalire, L.
Nydam, T.
Penenberg, D.
Hammel, P.
ANNALS OF ONCOLOGY, 2015, 26
[3] Phase II LAPACT trial of nab-paclitaxel (nab-P) plus gemcitabine (G) for patients with locally advanced pancreatic cancer (LAPC).
Hammel, Pascal
Lacy, Jill
Portales, Fabienne
Sobrero, Alberto F.
Cid, Roberto A. Pazo
Mozo, Jose Luis Manzano
Mozo, Manzano
Terrebonne, Eric
Dowden, Scot D.
Li, Jack Shiansong
Ong, Teng Jin
Nydam, Thom
Philip, Philip Agop
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04)
[4] Interim results of a multicenter phase II trial of nab-paclitaxel (nab-P) plus gemcitabine (G) for patients (Pts) with locally advanced pancreatic cancer (LAPC).
Lacy, Jill
Portales, Fabienne
Hammel, Pascal
Cid, Roberto A. Pazo
Mozo, Jose Luis Manzano
Kim, Edward Jae-hoon
Dowden, Scot D.
Borg, Christophe
Sastre, Javier
Bathini, Venu Gopal
Terrebonne, Eric
Lopez-Trabada, Daniel
Rivera, Fernando
Asselah, Jamil
Damiani, Azzurra
Hwang, Jimmy J.
Ong, Teng Jin
Nydam, Thom
Li, Jack Shiansong
Philip, Philip Agop
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (04)
[5] nab-Paclitaxel (nab-P) plus gemcitabine (G) for patients (Pts) with locally advanced pancreatic cancer (LAPC): Interim efficacy and safety results from the Phase 2 LAPACT Trial
Philip, P. A.
Lacy, J.
Portales, F.
Sobrero, A.
Pazo-Cid, R.
Manzano Mozo, J. L.
Kim, E. S.
Dowden, S.
Zakari, A.
Borg, C.
Terrebonne, E.
Rivera Herrero, F.
Shiansong Li, J.
Ong, T. J.
Nydam, T.
Hammel, P.
ANNALS OF ONCOLOGY, 2017, 28
[6] Phase II LAPACT Trial of Nab-Paclitaxel Plus Gemcitabine for Patients With Locally Advanced Pancreatic Cancer
Bekaii-Saab, Tanios
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2018, 16 (03) : 9 - 10
[7] Gemcitabine (Gem) and nab-paclitaxel (nab-P) in patients (pts) with refractory advanced pancreatic cancer
Palacio, Sofia
Akunyili, Ikechukwu Immanuel
Ernani, Vinicius
Macintyre, Jessica
Merchan, Jaime R.
Pollack, Terri
Reis, Isildinha
Restrepo, Maria H.
Lima, Caio Max S. Rocha
Hosein, Peter Joel
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (03)
[8] Interim health related quality of life (QoL) from LAPACT, a Phase 2 trial of nab-paclitaxel (nab-P) plus gemcitabine (G) for patients (Pts) with locally advanced pancreatic cancer (LAPC)
Portales, F.
Philip, P. A.
Hammel, P.
Buscaglia, M.
Pazo-Cid, R.
Manzano Mozo, J. L.
Kim, E. S.
Dowden, S.
Zakari, A.
Borg, C.
Terrebonne, E.
Rivera Herrero, F.
Li, J. Shiansong
Ong, T. J.
Nydam, T.
Lacy, J.
ANNALS OF ONCOLOGY, 2017, 28
[9] Gemcitabine (G) plus nab-paclitaxel (nab-P) plus chemoradiation (CRT) in locally advanced pancreatic cancer (LAPC)
Olowokure, Olugbenga Olanrele
Bedoya, Ivan Dario
Mierzwa, Michelle Lynn
Torregroza, Maria Patricia
Dwivedi, Alok Kumar
Wang, Jiang
Smith, Milton T.
Schmulewitz, Nathan
Kucera, Stephen
Choe, Kyuran Ann
Ristagno, Ross
Rudich, Steven
Sussman, Jeffrey J.
Ahmad, Syed A.
JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
[10] Nab-paclitaxel plus gemcitabine in patients with locally advanced pancreatic cancer (LAPACT): a multicentre, open-label phase 2 study
Philip, Philip A.
Lacy, Jill
Portales, Fabienne
Sobrero, Alberto
Pazo-Cid, Roberto
Manzano Mozo, Jose L.
Kim, Edward J.
Dowden, Scot
Zakari, Ahmed
Borg, Christophe
Terrebonne, Eric
Rivera, Fernando
Sastre, Javier
Bathini, Venu
Lopez-Trabada, Daniel
Asselah, Jamil
Saif, Muhammad Wasif
Li, Jack Shiansong
Ong, Teng Jin
Nydam, Thomas
Hammel, Pascal
LANCET GASTROENTEROLOGY & HEPATOLOGY, 2020, 5 (03): : 285 - 294

← 1 2 3 4 5 →